By Jonathan Stempel NEW YORK, Feb 23 (Reuters) - Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely ...
Bayer sued Johnson and Johnson, alleging false advertising for its prostate cancer drug Erleada, claiming it misleads patients.
Pharmaceutical manufacturer Johnson & Johnson is expanding its operations in Pennsylvania by building a new cell therapy ...
Feb 19 (Reuters) - Johnson & Johnson is preparing a potential sale of the orthopedics unit that it has been planning ...
It's about striking that perfect balance between chasing growth and protecting what you already have.
A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her ...
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.
InvestorsHub on MSN
Johnson & Johnson presents three-year TREMFYA data showing sustained ulcerative colitis outcomes
Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to deliver sustained clinical and endoscopic benefits over 140 weeks in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results